FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 18282 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| High in vitro activity of the novel antimicrobial gepotidacin against Neisseria gonorrhoeae isolates in eight WHO Enhanced Gonococcal Antimicrobial Surveillance Programme countries in three WHO regions, 2021-24. PMID 41400870 · J Antimicrob Chemother · 2026-Jan-06 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Levosimendan to Facilitate Weaning From ECMO in Patients With Severe Cardiogenic Shock: The LEVOECMO Randomized Clinical Trial. PMID 41324946 · JAMA · 2026-Jan-06 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| A Phase II Trial to Evaluate the Safety and Immunogenicity of Two Doses of a Folate Receptor Alpha Vaccine in Patients with Triple-Negative Breast Cancer. PMID 41213103 · Clin Cancer Res · 2026-Jan-06 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of once-weekly somatrogon following up to 4 years of treatment in Japanese children with growth hormone deficiency: results from an open-label extension of a phase 3 study. PMID 41183961 · Endocr J · 2026-Jan-06 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| First-line Anlotinib plus Anthracyclines and Ifosfamide Followed by Anlotinib Maintenance in Advanced Soft-Tissue Sarcoma: A Phase II Single-Arm Trial. PMID 41128656 · Clin Cancer Res · 2026-Jan-06 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| SPECTREM phase IIIb clinical trial results through week 16: guselkumab efficacy and safety for the treatment of low body surface area, moderate psoriasis with high-impact site involvement. PMID 40875818 · Br J Dermatol · 2026-Jan-06 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| The Impact of Concordance between Liquid and Tissue Biopsy for Actionable Mutations: Insights from the ROME Trial. PMID 40833744 · Clin Cancer Res · 2026-Jan-06 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of Cinainu in paediatric alopecia areata: an international, double-blind, randomized, placebo-controlled, phase II/III trial. PMID 40668972 · Br J Dermatol · 2026-Jan-06 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Exploring Trial Endpoints in Geographic Atrophy Based on Localized Functional Changes in Microperimetry and AI-Quantified OCT Biomarkers. PMID 41533918 · Invest Ophthalmol Vis Sci · 2026-Jan-05 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Safety, immunogenicity, and relative efficacy of a parenteral trivalent rotavirus subunit vaccine candidate (TV P2-VP8) in healthy Ghanaian, Malawian, and Zambian infants. PMID 41319434 · Vaccine · 2026-Jan-05 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Prevention of postoperative complications with negative pressure wound therapy after complex breast cancer surgery: a study protocol of a randomised controlled trial (TPN-SEIN). PMID 41485781 · BMJ Open · 2026-Jan-03 方案论文未报告临床试验结果。 |
H
S
B
|
严格 v3 独有 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of rocatinlimab for the treatment of moderate-to-severe atopic dermatitis in ROCKET-IGNITE and ROCKET-HORIZON: two global, double-blind, placebo-controlled, randomised phase 3 clinical trials. PMID 41314226 · Lancet · 2026-Jan-03 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Economic Evaluation of Tobacco Treatments From the Screen ASSIST Lung Cancer Screening Trial. PMID 41575745 · JAMA Netw Open · 2026-Jan-02 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Impact of secukinumab with modified nourishing blood and moisturising decoction on superficial fungal infections in patients with psoriasis with blood-dryness pattern. PMID 41528783 · J Wound Care · 2026-Jan-02 The study evaluates a drug intervention in a randomized trial for psoriasis, which is not an oncologic malignancy. Therefore, it is excluded from the oncology Kaplan-Meier digitization cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Long-Term Survival Outcomes of NCRT With Surgery vs Surgery With Adjuvant Therapy for ESCC: A Single-Center Prospective Phase 3 Randomized Clinical Trial. PMID 41490111 · JAMA Netw Open · 2026-Jan-02 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| A Randomized Clinical Trial of Kidney Autologous Cell Therapy in Diabetic Kidney Disease. PMID 41481370 · Clin J Am Soc Nephrol · 2026-Jan-02 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| [177Lu]Lu-DOTATATE for Recurrent Meningioma (LUMEN-1, EORTC-2334-BTG): Study Protocol for a Randomized Phase II Trial. PMID 40774695 · J Nucl Med · 2026-Jan-02 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| A prospective randomized study of sequential boost versus simultaneous integrated boost intensity-modulated radiation therapy with concurrent chemotherapy in locally advanced head and neck cancer. PMID 41910297 · J Cancer Res Ther · 2026-Jan-01 While the trial meets most criteria (oncology, human, randomized, time-to-event, drug intervention, original results), the phase is not explicitly confirmed as Phase III/IIIb or Phase II/III in the title, abstract, or metadata. Eligibility requires explicit establishment of all criteria, including trial phase. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| B-STARS2: Early contralesional continuous theta burst stimulation (cTBS) to promote upper limb recovery after stroke - Rationale and design of a phase-3 multicentre, randomised, sham-controlled, clinical trial. PMID 41614522 · Eur Stroke J · 2026-Jan-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Citicoline Triggers Proteome Remodeling and Proteostatic Adaptation: Evidence from Shotgun Proteomics. PMID 41599168 · Pharmaceutics · 2026-Jan-01 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Cabozantinib for advanced grade 3 neuroendocrine tumors: subgroup analysis of the phase 3 CABINET trial (Alliance A021602). PMID 41524552 · Endocr Relat Cancer · 2026-Jan-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
B
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Topical Efinaconazole 10% for Onychomycosis: Pooled Phase 3 Analysis in White, Black, and Asian Participants. PMID 41493257 · J Drugs Dermatol · 2026-Jan-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Efficacy, safety, and immunogenicity of UB-851 versus ® in patients with renal anemia receiving hemodialysis: A randomized, double-masked, phase III trial. PMID 41396155 · J Chin Med Assoc · 2026-Jan-01 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Anesthesia Type during Cancer Surgery: Results of the GA-CARES Randomized, Multicenter Trial. PMID 41363871 · Anesthesiology · 2026-Jan-01 The study is an oncology randomized trial with a time-to-event primary endpoint (all-cause mortality) and is an original result report. However, the intervention is a type of general anesthesia (propofol vs. volatile agent) used during cancer surgery, not a systemic or targeted drug therapy for the cancer itself. The drug intervention criterion requires a drug-containing cancer treatment (e.g., chemotherapy, immunotherapy, targeted therapy). Anesthesia choice is a perioperative supportive care intervention, not a cancer-directed drug intervention. Phase III status is not explicitly stated in the provided metadata. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Neonatal BCG vaccination to prevent respiratory infections in the first 5 years of life: results from the MIS BAIR randomised controlled trial. PMID 41337911 · Vaccine · 2026-Jan-01 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Optimal Duration of Androgen Deprivation Therapy With Definitive Radiotherapy for Localized Prostate Cancer: A Meta-Analysis. PMID 41264309 · JAMA Oncol · 2026-Jan-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of clevidipine emulsion injection compared with nicardipine in patients with hypertensive emergencies: a randomized, single-blind, positive-parallel-controlled, phase III clinical trial. PMID 41231022 · J Hypertens · 2026-Jan-01 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Immunogenicity and safety of a SARS-CoV-2 N-terminal domain and receptor-binding domain monovalent XBB.1.5 vaccine in Japanese participants. PMID 41223690 · Vaccine · 2026-Jan-01 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Laparoscopic vs Open Distal Gastrectomy With D2 Lymphadenectomy for Clinical T4a Gastric Cancer: The UMC-UPPERGI-01 Randomized Clinical Trial. PMID 41222957 · JAMA Surg · 2026-Jan-01 The record is a randomized trial in oncology with original results, but it is excluded because it does not meet the required Phase (likely Phase II, not explicitly Phase III/IIIb or Phase II/III), does not have a time-to-event efficacy endpoint (focus is on short-term surgical outcomes), and does not involve a drug-containing intervention (surgical procedures only). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Atorvastatin and Aortic Stiffness During Anthracycline-Based Chemotherapy: A Secondary Analysis of a Randomized Clinical Trial. PMID 41205202 · JAMA Cardiol · 2026-Jan-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Efficacy of Acoramidis in Wild-Type and Variant Transthyretin Amyloid Cardiomyopathy: Results From ATTRibute-CM and Its Open-Label Extension. PMID 41205147 · JAMA Cardiol · 2026-Jan-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Effects of aprocitentan on prognostically relevant ambulatory blood pressure-derived variables in resistant hypertension. PMID 41195725 · J Hypertens · 2026-Jan-01 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Early palliative care for patients with glioblastoma: A randomized phase III clinical trial (EPCOG). PMID 41071052 · Neuro Oncol · 2026-Jan-01 The trial is a randomized Phase III study in human glioblastoma (oncology) with a primary QoL endpoint and secondary palliative care outcomes. It is not a drug intervention trial (EIPC is a palliative care intervention, not a drug). The reported results include a survival difference (P=.018) but do not present it as a primary/key secondary time-to-event efficacy endpoint with Kaplan-Meier curves or hazard ratios. Therefore, it fails the drug intervention and time-to-event endpoint criteria. |
H
L
S
B
|
旧组与严格 v3 交集 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Radioiodine Plus Low-Dose Lenvatinib in Radioiodine-Sensitive High-Volume Metastatic Differentiated Thyroid Cancer: A Pilot Study. PMID 41021893 · Clin Nucl Med · 2026-Jan-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Long-Term Ozanimod Therapy in Patients With Moderately Active Ulcerative Colitis After Failure of 5-Aminosalicylic Acid. PMID 41003640 · Inflamm Bowel Dis · 2026-Jan-01 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Anti-TNF Therapies Promote a Proximal-to-Distal Healing Pattern in Moderate-to-Severe Ulcerative Colitis. PMID 40997114 · Inflamm Bowel Dis · 2026-Jan-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
B
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Effect of intraoperative low-dose esketamine on postoperative quality of recovery in patients undergoing laparotomy for gynecologic malignancy: a randomized controlled trial. PMID 40990647 · Int J Surg · 2026-Jan-01 While the study is a randomized, oncology drug trial with original results, it does not meet the required primary/key secondary time-to-event efficacy endpoint criterion (OS, PFS, DFS, EFS, RFS, TTP, or analysis via Kaplan-Meier/HR). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Juvenile Spondyloarthritis Disease Activity Index Validation in Enthesitis-Related Arthritis and Juvenile Psoriatic Arthritis in a Prospective Clinical Trial Setting. PMID 40953957 · J Rheumatol · 2026-Jan-01 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Impact of D3 lymph node dissection extent on postoperative bowel function and nutritional status in right-sided colon cancer: a prospective randomized controlled trial. PMID 40928287 · Int J Surg · 2026-Jan-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Effects of Resistance versus High-Intensity Interval Training on Myokines and Cancer Cell Suppression in Breast Cancer Survivors: A Randomized Trial. PMID 40903011 · Med Sci Sports Exerc · 2026-Jan-01 The study is a randomized trial in oncology but fails on multiple required criteria: no drug intervention, no specified definitive phase, and no time-to-event endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of SHR-1701 combined with chemoradiotherapy as neoadjuvant treatment for locally advanced rectal cancer. PMID 40876501 · Cancer Lett · 2026-Jan-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Self-Perceived Hearing Outcomes With Radiation and Cisplatin or Radiation and Cetuximab for Patients With Human Papilloma Virus (HPV)-Positive Oropharyngeal Cancer-Results From NRG Oncology RTOG 1016. PMID 40829719 · Int J Radiat Oncol Biol Phys · 2026-Jan-01 This is a secondary analysis of a Phase III randomized trial in oncology with a drug intervention, but it does not report a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS). The endpoint is a patient-reported outcome (hearing handicap). |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A multicenter randomized controlled trial of intrapleural perfusion of methotrexate-loaded tumor cell-derived microparticles combined with systemic therapy for malignant pleural effusion. PMID 40818045 · Int J Cancer · 2026-Jan-01 The study is a randomized, controlled, human oncology trial with a drug intervention and primary time-to-event endpoint (OS). However, it is not explicitly identified as a Phase III or Phase II/III trial. The abstract and metadata do not specify the trial phase. Per the adjudication rules, the phase must be explicitly established to be eligible; it cannot be inferred. Therefore, it does not meet the 'phase3_or_definitive' criterion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| HYPofractionated Adjuvant RadioTherapy in 1 Versus 2 Weeks in High-Risk Patients With Breast Cancer (HYPART): Acute Toxicity Results. PMID 40780546 · Int J Radiat Oncol Biol Phys · 2026-Jan-01 The report is an original result from a randomized Phase III oncology trial in humans, but the intervention is radiation therapy without a drug component, and the primary endpoint reported is acute toxicity, not a time-to-event efficacy outcome like OS, PFS, DFS, EFS, RFS, TTP, or its associated Kaplan-Meier/HR analysis. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Late Toxicities and Quality of Life After a Radiation Boost for Breast Ductal Carcinoma In Situ: Boost or No Boost in DCIS Randomized Trial. PMID 40752655 · Int J Radiat Oncol Biol Phys · 2026-Jan-01 The record is a Phase III randomized trial in oncology (breast DCIS) with a time-to-event primary endpoint (local recurrence-free survival). However, the intervention is radiation therapy (a non-drug modality). The current report is an original results paper, but it explicitly covers only secondary endpoints (toxicity, quality of life) because the primary endpoint has not been reached. It therefore does not meet the criterion of reporting the primary/key secondary time-to-event efficacy endpoint. The drug intervention criterion also fails. |
H
L
S
B
|
旧组与严格 v3 交集 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Randomized, double-blind phase III trial of a dexamethasone-free regimen for managing highly emetogenic chemotherapy-induced nausea and vomiting. PMID 40735921 · Int J Cancer · 2026-Jan-01 The trial is a randomized, phase III oncology study with drug interventions, but its primary endpoint is a categorical response rate (complete response), not a time-to-event endpoint such as OS, PFS, or DFS. There is no mention of Kaplan-Meier analysis or hazard ratios. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Pain relief by targeting nonrestorative sleep in fibromyalgia: a phase 3 randomized trial of bedtime sublingual cyclobenzaprine. PMID 40627411 · Pain Med · 2026-Jan-01 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Low-dose Radiation Therapy Concurrent With Atezolizumab and Chemotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer: 3-Year Follow-up of a Multicenter, Single-arm, Phase 2 Trial (MATCH). PMID 40609842 · Int J Radiat Oncol Biol Phys · 2026-Jan-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Comparative study of Chinese herbal enema combined with mesalazine vs mesalazine alone in the treatment of ulcerative colitis: A randomized controlled trial. PMID 40533886 · J Chin Med Assoc · 2026-Jan-01 The study is a randomized controlled trial with a drug intervention (mesalazine) and reports primary efficacy results. However, it is excluded because it is not an oncology study (focus on ulcerative colitis) and does not have a time-to-event efficacy endpoint (OS, PFS, DFS, etc.) as required. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| The relationship between mean arterial pressure and terlipressin in hepatorenal syndrome-acute kidney injury reversal: A post hoc analysis. PMID 40053863 · Hepatology · 2026-Jan-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |